通过构成约束来设计衍生物作为α2A-腺素受体选择性激动剂
Xucheng Lv1, Peilan Zhou1, Xuehong Qiao1,2
1Beijing Institute of Pharmacology and Toxicology, Haidian District, Beijing 100850, China.
研究人员开发了具有提高选择性的新型α2A-腺受体 (α2A-AR) 激动剂. 化合物A9和B9显示出高强度和选择性,比现有药物具有潜在的治疗优势.
科学领域:
- 药理学 药理学是指药理学的学科.
- 药用化学 医学化学
- 神经科学是一个神经科学.
背景情况:
- 选择性α2-上腺受体 (α2A-AR) 激动剂对于各种治疗应用至关重要.
- 提高α2A-AR激动剂的选择性仍然是药物开发中的一个重大挑战.
研究的目的:
- 设计和合成新型的α2A-AR激动剂,使用构造约束方法提高选择性.
- 评估合成化合物的体外和体外药理学概况.
主要方法:
- 基于结构的药物设计,使用美德托米丁作为起点.
- 合成衍生物和结构-活性关系 (SAR) 研究.
- 在体外受体结合和功能测试 (EC50测定).
- 在体内研究评估了小鼠对正反射的损失 (ED50的确定).
- 分子建模和位点定向突变发生,以阐明结合模式.
主要成果:
- 化合物A9和B9对α2A-AR具有很高的亲和力和疗效,EC50值分别为0.78nM和0.23nM.
- A9和B9的选择性比德克斯梅丁胺 (DMED) 的选择性大10至80倍.
- 在体内研究证实了A9和B9的强烈镇静作用,ED50值分别为1.54 mg/kg和0.138 mg/kg.
- 结合性研究强调了ASP1283.32与激动剂之间键的关键作用.
- 与DMED不同,A9和B9没有表现出双重逆药理效应.
结论:
- 构造约束方法成功产生了高度选择性的α2A-AR激动剂,A9和B9.
- 这些新型化合物具有优越的选择性和效力,与德克斯梅德托米丁相比.
- 这些发现为选择性α2A-AR激动症的结构要求提供了宝贵的见解,并为进一步的治疗开发提供了有前途的候选人.
更多相关视频
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
18:45Harvesting and Cryo-cooling Crystals of Membrane Proteins Grown in Lipidic Mesophases for Structure Determination by Macromolecular Crystallography
Published on: September 2, 2012
相关概念视频
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
The direct-acting...
Adrenergic Agonists: Direct-Acting Agents
These agents can be classified...
Adrenergic Receptors: ɑ Subtype
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship
